OAB-14 as a Potential Treatment for Alzheimer’s Disease: Apolipoprotein E3 as a Potential Mechanism for Improvement of Cognitive Deficits
OAB-14 as a Potential Treatment for Alzheimer’s Disease: Apolipoprotein E3 as a Potential Mechanism for Improvement of Cognitive Deficits
OAB-14 作为阿尔茨海默病的潜在治疗方法：载脂蛋白 E3 作为改善认知缺陷的潜在机制
批准号：
486163
负责人：
Taylor Makenna
金额：
$1.27万
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2022
资助国家：
加拿大
项目状态：
已结题
起止时间：
2022-12-01 至 2023-12-01
中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Alzheimer’s disease (AD) is a neurodegenerative disease in the central nervous system that causes devastating impairments in memory, judgment and emotions and ultimately results in death.1,2 Late-onset (>65 years old) AD (LOAD) accounts for the majority
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金
